A clinical trial conducted in Tanzania and Mozambique and published in The Lancet Infectious Diseases concludes that expanding the use of molecular diagnostic tests on urine and stool samples, in ...

The panel discusses unmet needs that remain in the treatment and management of HIV. Adam C. Welch, PharmD, MBA: Let’s talk a little about the future of care in HIV and some of the unmet needs and ...

The treatment landscape for HIV is discussed by a panel led by Dr Welch. Adam C. Welch, PharmD, MBA: Let’s get into some of those treatments. Shauna, can you provide an overview of how we treat HIV?

HIV is not curable for the wider population as of this writing, and as a result we've rated the claim mostly false. A small ...

Since the HIV epidemic began, the diagnosis of HIV has evolved from a death sentence to a chronic, but manageable condition by starting and staying on treatment. HIV treatment can help people live ...

People living with HIV need to take antiretroviral treatment for life to prevent the virus from multiplying in their body. But some people, known as 'post-treatment controllers,' have been able to ...

Gilead’s Tomas Cihlar and his team of researchers have spent decades studying HIV—and their latest innovation could be a game ...

The FDA accepted an NDA for a bictegravir and lenacapavir single-tablet regimen for adults with HIV-1 who have achieved virologic suppression.

The Food and Drug Administration has approved Sunlenca, an injectable therapy to suppress HIV for patients who suffered drug resistance to other regimens. Experts say the new injectable, which works ...

Reductions in US global health aid are disrupting HIV prevention and treatment programs in South Africa, potentially ...

Gilead Sciences has secured a good start to 2026 with its human immunodeficiency (HIV) medicines amid the backdrop of a generally positive first quarter. During Q1 2026, Gilead’ ...